Integra LifeSciences IART Accrued Progress Collections and Price Adjustments

Accrued Progress Collections and Price Adjustments at other companies

ITG

Integer HoldingsITGR

——

Merit Medical SystemsMMSI

——

Establishment LabsESTA

——

Henry ScheinHSIC

——

Envista Holdings CorporationNVST

——

Other financials

Income statement

See full

Revenue$391.9M+2.4%

Gross profit$217.0M+11.6%

Operating income$11.5M+174%

Net income-$4.6M+81.7%

EPS (diluted)-$0.06+81.8%

Balance sheet

See full

Cash & equivalents$236.8M-1.0%

Total debt$2.0B+3.2%

Total equity$1.0B-31.6%

Total assets$3.6B-11.7%

Cash flow

See full

Operating cash flow$9.8M+187%

CapEx$14.8M-48.7%

Free cash flow-$5.0M+87.4%

Valuation

See full

Market cap$1.38B+53.4%

Enterprise value$3.12B+21.1%

P/S0.8×+0.3×

Profitability

See full

Gross margin51.9%-1.6pp

Operating margin-29.8%-30.3pp

Net margin-30.1%—

FCF margin3.8%-6.3pp

Returns & leverage

See full

Return on equity-38.6%—

Debt / equity1.9×+0.6×

Current ratio3.4×+2.2×

Where this comes from

Reported directly by Integra LifeSciences in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.

The official record: Integra LifeSciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Integra LifeSciences's accrued progress collections and price adjustments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Integra LifeSciences's accrued progress collections and price adjustments?: Integra LifeSciences (IART) reported accrued progress collections and price adjustments of $10.8M in Q1 2026.
How has Integra LifeSciences's accrued progress collections and price adjustments changed year-over-year?: Integra LifeSciences's accrued progress collections and price adjustments increased by 14.9% year-over-year, from $9.4M to $10.8M.